| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Edoxaban versus warfarin in patients with atrial fibrillation.
|
N Engl J Med
|
2013
|
7.70
|
|
2
|
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
|
Lancet
|
2015
|
2.57
|
|
3
|
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
|
Lancet
|
2015
|
2.04
|
|
4
|
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
|
Am Heart J
|
2010
|
1.91
|
|
5
|
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
|
J Am Coll Cardiol
|
2014
|
1.45
|
|
6
|
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
|
Nat Rev Drug Discov
|
2010
|
1.33
|
|
7
|
Update on anti-coagulation in atrial fibrillation.
|
QJM
|
2011
|
1.28
|
|
8
|
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
|
Circulation
|
2016
|
1.07
|
|
9
|
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.
|
Eur Heart J
|
2013
|
1.03
|
|
10
|
New oral anticoagulants may be particularly useful for asian stroke patients.
|
J Stroke
|
2014
|
1.00
|
|
11
|
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
|
Thromb Haemost
|
2012
|
0.97
|
|
12
|
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
|
Stroke
|
2014
|
0.87
|
|
13
|
A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
|
Br J Clin Pharmacol
|
2013
|
0.85
|
|
14
|
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.
|
Europace
|
2012
|
0.84
|
|
15
|
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
|
J Am Heart Assoc
|
2016
|
0.80
|
|
16
|
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
|
J Am Heart Assoc
|
2016
|
0.78
|
|
17
|
Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease.
|
Thrombosis
|
2012
|
0.78
|
|
18
|
Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.
|
JAMA Cardiol
|
2016
|
0.78
|
|
19
|
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
|
J Am Coll Cardiol
|
2016
|
0.77
|
|
20
|
Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.
|
J Am Heart Assoc
|
2016
|
0.77
|
|
21
|
Efficacy and safety of novel anticoagulants compared with established agents.
|
Ther Adv Hematol
|
2011
|
0.77
|
|
22
|
Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.
|
Vasc Health Risk Manag
|
2013
|
0.76
|
|
23
|
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
|
Stroke
|
2016
|
0.75
|
|
24
|
The need for multicentre cardiovascular clinical trials in Asia.
|
Nat Rev Cardiol
|
2013
|
0.75
|
|
25
|
Improving anticoagulation management in patients with atrial fibrillation.
|
P T
|
2013
|
0.75
|
|
26
|
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
|
J Am Heart Assoc
|
2016
|
0.75
|
|
27
|
Edoxaban.
|
Hosp Pharm
|
2015
|
0.75
|
|
28
|
Stroke prevention in atrial fibrillation: latest clinical trials and guidelines.
|
Pharmaceuticals (Basel)
|
2012
|
0.75
|
|
29
|
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
|
J Am Soc Echocardiogr
|
2016
|
0.75
|
|
30
|
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
|
Circ Arrhythm Electrophysiol
|
2017
|
0.75
|